Project Grant R03CA270278
Award Date
9/15/23
Completion Date
8/31/25
Dollars Obligated
$177K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Children's Hospital Corporation, doing business as Boston Children's Hospital, supports research to identify genes and pathways that are suppressed during early tumor development, enabling cancers to evade immune surveillance. The $901,205 award, which began on Jul 3, 2025 and runs through Jun 30, 2032, will leverage genetically engineered mouse models and advanced genomic and spatial...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $518,219 in funding to the University of Pittsburgh to conduct research aimed at deciphering the molecular mechanisms underlying the development of cholangiocarcinoma (CCA), a deadly form of liver cancer. The key objectives of this 5-year research project are to: Investigate the intertwined roles of the nuclear receptors FXR and CAR in promoting the malignant transformation of hepatocytes...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The $172,193 grant, awarded on May 7, 2025, supports a 5-year research project to characterize gene regulatory elements and metabolic functions in a rare and aggressive form of renal cell carcinoma known as translocation renal cell carcinoma (TRCC). The research aims to develop optimization methods to...
This Project Grant award of $223,176 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to define the role of stress granules in cancer initiation. The primary awardee, The Children's Hospital Corporation doing business as Boston Children's Hospital, will leverage a humanized zebrafish melanoma model to investigate how stress granules formed in melanoma precursor cells impact tumor development and progression. The research aims to elucidate the...
The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...
This is a $1,593,000 federal Project Grant awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant was awarded on September 1, 2023 to The Children's Hospital Corporation, doing business as Boston Children's Hospital, a non-profit pediatric teaching hospital and research center. The funding supports a 3-year research project to "DEFINING THE UNIVERSAL GENOMIC LANGUAGE OF HALLMARKS IN TUMOR...
The National Cancer Institute (NCI) awarded a $514,196 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The grant, which runs from September 1, 2024 to April 2, 2027, will support research to investigate IGF2BP1 as a novel therapeutic target for Ewing sarcoma, the second most prevalent bone cancer among children. The project aims to validate IGF2BP1 as an Ewing sarcoma dependency, determine the molecular...
The National Cancer Institute (NCI) awarded a $788,589 Project Grant (CFDA 93.398 Cancer Research Manpower) to Children's Hospital Los Angeles (CHLA) on August 15, 2024. The grant supports research to understand how the transcription factor FOXR2 cooperates with ETS transcription factors to drive the formation of diffuse midline gliomas, a devastating type of childhood brain tumor. The research aims to elucidate the role of MAPK signaling in FOXR2-expressing gliomas and test if ETS transcription...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $402,400.00 to the University of Hawaii at Manoa to conduct research on targeting neutrophilic myeloid-derived suppressor cells (PMN-MDSCs) for immunotherapy of hepatoblastoma, a rare and deadly childhood liver cancer. The research aims to determine the oncogenic drivers of PMN-MDSC recruitment in hepatoblastoma and evaluate the therapeutic potential of a CXCR2 inhibitor, both alone and...